Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
nab paclitaxel plus gemcitabine
DRUG
2 trials
Sponsors
Asan Medical Center
, Fudan University
Conditions
Borderline Resectable Pancreatic Cancer
Locally Advanced Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Pancreatic Cancer
Phase 3
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
NCT04617821
Fudan University
Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Start: 2021-09-01
End: 2024-09-30
Target: 300
Updated: 2022-01-28
Unknown Phase
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Completed
NCT04133155
Asan Medical Center
Metastatic Pancreatic Cancer, Pancreatic Cancer
Start: 2019-09-16
End: 2020-02-01
Updated: 2020-03-13
Related Papers
Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
Therapeutic Advances in Medical Oncology
2020-01-01
20 citations